The present of Fab (fragment of anti-TfR mAb) increased β-amyloid target engagement in a mouse model of Alzheimer’s disease by 55-fold compared to the free antibody. The gene discussed is TFRC; the disease is early-onset autosomal dominant Alzheimer disease.